Results 161 to 170 of about 1,649 (205)
Formulation and evaluation of proniosomes containing lornoxicam
Drug Delivery and Translational Research, 2016 © 2016, Controlled Release Society. Proniosomes are the new generation provesicular drug delivery system of non-ionic surfactant, lecithin and cholesterol which upon reconstitution get converted into niosomes.
Jyotsana R Madan, Kamal Dua, Dua Kamal
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Presumptive Lornoxicam Intoxication in Four Dogs
Topics in Companion Animal Medicine, 2021Lornoxicam is a nonsteroidal anti-inflammatory drug extensively used in human medicine, which is not approved for canine use. Lornoxicam intoxication has been rarely reported in dogs. Four dogs of various breeds, aged 7 months to 10 years, were admitted with a recent history of melena, anorexia and depression, occurring 1-4 days after the ingestion of ...
Vicky, Karakitsou +7 more
openaire +2 more sources
2011
A comprehensive profile on lornoxicam, the oxicam nonsteroidal anti-inflammatory agent which is used in the muscular skeletal and joint disorders such as osteoarthritis and rheumatoid arthritis, is prepared. This profile contains the following sections: description, uses and applications, methods of preparation, physical characteristics, methods of ...
Mahrous O, Ahmed, Abdullah A, Al-Badr
openaire +3 more sources
A comprehensive profile on lornoxicam, the oxicam nonsteroidal anti-inflammatory agent which is used in the muscular skeletal and joint disorders such as osteoarthritis and rheumatoid arthritis, is prepared. This profile contains the following sections: description, uses and applications, methods of preparation, physical characteristics, methods of ...
Mahrous O, Ahmed, Abdullah A, Al-Badr
openaire +3 more sources
Effect of the CYP2C9*3 allele on lornoxicam metabolism
Clinica Chimica Acta, 2006We investigated whether the CYP2C9 genotypes would affect lornoxicam metabolism in healthy volunteers.Twelve healthy volunteers who had been genotyped for CYP2C9 gene were selected to participate in our study. After 8 mg lornoxicam was taken, blood samples were drawn from 0 to 36 h.
Zhao-Qian Liu, Yi-Jing He
exaly +3 more sources
Clinical Pharmacokinetics of Lornoxicam
Clinical Pharmacokinetics, 1998Lornoxican (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5'-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation.
N M, Skjodt, N M, Davies
openaire +2 more sources
European Journal of Anaesthesiology, 2010
Nonsteroidal anti-inflammatory drugs have peripheral analgesic effects. We compared the efficacy of peritonsillar infiltration versus intravenous (i.v.) lornoxicam on pain relief after tonsillectomy in adults.Sixty adult patients scheduled for tonsillectomy were randomly assigned into three groups in a double-blind placebo-controlled study.
Salah A, Ismail, Hany A, Mowafi
openaire +2 more sources
Nonsteroidal anti-inflammatory drugs have peripheral analgesic effects. We compared the efficacy of peritonsillar infiltration versus intravenous (i.v.) lornoxicam on pain relief after tonsillectomy in adults.Sixty adult patients scheduled for tonsillectomy were randomly assigned into three groups in a double-blind placebo-controlled study.
Salah A, Ismail, Hany A, Mowafi
openaire +2 more sources
Drugs, 1996
Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a ...
J A, Balfour, A, Fitton, L B, Barradell
openaire +2 more sources
Lornoxicam (chlortenoxicam), a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties, is available in oral and parenteral formulations. It is distinguished from established oxicams by a relatively short elimination half-life (3 to 5 hours), which may be advantageous from a ...
J A, Balfour, A, Fitton, L B, Barradell
openaire +2 more sources
Lornoxicam in clinical practice.
Postgraduate medical journal, 1991Three studies reported here have confirmed that lornoxicam is effective in osteoarthritis and the ideal dose appears to be 12 mg daily. Overall, lornoxicam appears to be a useful drug in the treatment of both osteo- and rheumatoid arthritis, from the data presently available.
H, Berry, S, Ollier
openaire +1 more source
Pharmacokinetics of lornoxicam in man.
Postgraduate medical journal, 1991Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam. Lornoxicam was administered as an aqueous solution both orally and intravenously to young, healthy, male volunteers. The total excretion of lornoxicam via urine and faeces after oral administration was determined by administering 14C-labelled ...
G, Hitzenberger +3 more
openaire +1 more source